We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » New Transplant Guidance Recommends Endpoints, Trial Designs for CMV Drugs
New Transplant Guidance Recommends Endpoints, Trial Designs for CMV Drugs
Sponsors of drugs to treat or prevent cytomegalovirus (CMV) disease in organ or stem cell transplant patients may use CMV blood levels (CMV viremia) as a validated surrogate endpoint, according to a guidance the FDA finalized last week.